2. Academic Validation
  3. Synthesis, in vitro and in silico evaluation of novel trans-stilbene analogues as potential COX-2 inhibitors

Synthesis, in vitro and in silico evaluation of novel trans-stilbene analogues as potential COX-2 inhibitors

  • Bioorg Med Chem. 2018 Jan 1;26(1):141-151. doi: 10.1016/j.bmc.2017.11.027.
Miłosz Regulski 1,  Hanna Piotrowska-Kempisty 2,  Wiesław Prukała 3,  Zbigniew Dutkiewicz 4,  Katarzyna Regulska 5,  Beata Stanisz 6,  Marek Murias 7
Affiliations

Affiliations

  • 1 Poznan University of Medical Sciences, Department of Toxicology, 30 Dojazd Street, 60-631 Poznań, Poland. Electronic address: miloszregulski@ump.edu.pl.
  • 2 Poznan University of Medical Sciences, Department of Toxicology, 30 Dojazd Street, 60-631 Poznań, Poland.
  • 3 Adam Mickiewicz University in Poznań, Faculty of Chemistry, Nucleosides and Nucleotides Chemistry, 89b Umultowska Street, 61-614 Poznań, Poland.
  • 4 Poznan University of Medical Sciences, Department of Chemical Technology of Drugs, 6 Grunwaldzka Street, 60-780 Poznań, Poland.
  • 5 Greater Poland Oncology Center, Clinical Pharmacy, 15 Garbary Street, 61-866 Poznań, Poland.
  • 6 Poznan University of Medical Sciences, Department of Pharmaceutical Chemistry, 6 Grunwaldzka Street, 60-780 Poznań, Poland.
  • 7 Poznan University of Medical Sciences, Department of Toxicology, 30 Dojazd Street, 60-631 Poznań, Poland. Electronic address: marek.murias@ump.edu.pl.
PMID: 29191502 DOI: 10.1016/j.bmc.2017.11.027
Abstract

25 new trans-stilbene and trans-stilbazole derivatives were investigated using in vitro and in silico techniques. The selectivity and potency of the compounds were assessed using commercial ELISA test. The obtained results were incorporated into 2D QSAR assay. The most promising compound 4-nitro-3',4',5'-trihydroxy-trans-stilbene (N1) was synthetized and its potency and selectivity were confirmed. N1 was classified as preferential COX-2 Inhibitor. Its ability to inhibit COX-2 in MCF-7 cell line was established and its cytotoxicity by MTT test was assessed. The compound was more cytotoxic than celecoxib within studied concentration range. Finally, the investigated trans-stilbene was docked into COX-1 and COX-2 active sites using "CDOCKER" protocol.

Figures